Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET

NCT03083210 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Neuroendocrine Tumors

Interventions

DRUG: Lanreotide

Sponsor

Samsung Medical Center